Clinical Trial Update: Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG） [Phase 3]

View source ↗

Summary

Phase 3 trial comparing alflutinib mesylate to gefitinib in locally advanced or metastatic EGFR-sensitizing mutation-positive non-small cell lung cancer; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alflutinib Mesylate (alflutinib)
• Gefitinib (Gefitinib)

Snippet

Sponsor: Allist Pharmaceuticals, Inc. | Conditions: Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING